For research use only. We do not sell to patients.


CAS No. : 247257-48-3

Biological Activity:Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.
IC50 value:
Target: AT1 receptor antagonist
in vitro: Fimasartan suppressed the expressions of inducible nitric oxide synthase (iNOS) by down-regulating its transcription, and subsequently inhibited the productions of nitric oxide (NO). In addition, fimasartan attenuated LPS-induced transcriptional and DNA-binding activities of nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1) [1]. BR-A-657 displaced [125I][Sar1
-Ile8]angiotensin II (Ang II) from its specific binding sites to AT1 subtype receptors in membrane fractions of HEK-293 cells with an IC50 of 0.16 nM [2].
in vivo: After oral administration of 240 mg fimasartan, the mean area under the plasma concentration-time curve from time zero to infinity was 2899.0 ng/ml/h in the older, which was significantly greater than in young subjects (1767.4 ng/ml/h; p = 0.03) [3]. Compared with atorvastatin alone, coadministration of fimasartan and atorvastatin increased the atorvastatin acid mean (95% confidence interval) maximum concentration (Cmax,ss) by 1.89-fold (1.49-2.39) and the area under the concentration curve (AUCτ,ss) by 1.19-fold (0.96-1.48). Fimasartan also increased the mean 2-hydroxy atorvastatin acid Cmax,ss and AUCτ,ss by 2.45-fold (1.80-3.35) and 1.42-fold (1.09-1.85), respectively [4].

Research Area:Cardiovascular Disease|Endocrinology

Targets:Angiotensin Receptor|Apoptosis

Related Screening Libraries:Drug Repurposing Compound Library Plus;FDA-Approved Drug Library Plus;FDA-Approved Drug Library Mini;Bioactive Compound Library Plus;Apoptosis Compound Library;GPCR/G Protein Compound Library;FDA-Approved Drug Library;Drug Repurposing Compound Library;Anti-Cardiovascular Disease Compound Library;Endocrinology Compound Library;Anti-COVID-19 Compound Library;Orally Active Compound Library;Neurotransmitter Receptor Compound Library;FDA Approved & Pharmacopeial Drug Library;Angiogenesis-Related Compound Library;Human Metabolite Library;Anti-Prostate Cancer Compound Library;

Related Small Molecules:Physalin A;Bomedemstat ditosylate;Enpp/Carbonic anhydrase-IN-1;GK563;Calpeptin;Lobetyolin;BJE6-106;Dinaciclib;Ecteinascidin 770;MDM2-p53-IN-15;AT9283;Staurosporine;SNS-032;C188-9;ZLDI-8;Topoisomerase I/II inhibitor 3;Xevinapant;Mangiferin;Cambinol;Antioxidant agent-5;Apoptosis inducer 9;Bafetinib;Cyclovirobuxine D;STAT3-IN-10;Rigosertib sodium

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

About Us:

  • MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use;
  • Structurally and synthetically diverse biologically active compounds;
  •  roduct quality is the key to our success and we take pride in offering only the highest-grade products.;
  • We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.;
  • Product identity, quality, purity and activity are assured by our robust quality control programs and procedures.;
  • Structurally and synthetically diverse biologically active compounds;

  • Customized order volume ranging from milligrams to kilograms scale;
  • We provide customer-oriented services. To explore more, please contact us at [email protected]. Our team will gladly assist you.

50K Diversity Library
Top Publications Citing Use of MCE Products
Recombinant Proteins